YU46665B - Postupak za dobijanje peptida i novi peptidi - Google Patents

Postupak za dobijanje peptida i novi peptidi

Info

Publication number
YU46665B
YU46665B YU191887A YU191887A YU46665B YU 46665 B YU46665 B YU 46665B YU 191887 A YU191887 A YU 191887A YU 191887 A YU191887 A YU 191887A YU 46665 B YU46665 B YU 46665B
Authority
YU
Yugoslavia
Prior art keywords
insulin
amino acid
acid residues
peptides
molecule
Prior art date
Application number
YU191887A
Other languages
English (en)
Serbo-Croatian (sh)
Other versions
YU191887A (en
Inventor
K.H. Joergensen
Original Assignee
Novo Nordisk A/S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK503386A external-priority patent/DK503386D0/da
Priority claimed from DK356987A external-priority patent/DK356987D0/da
Application filed by Novo Nordisk A/S. filed Critical Novo Nordisk A/S.
Publication of YU191887A publication Critical patent/YU191887A/xx
Publication of YU46665B publication Critical patent/YU46665B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
YU191887A 1986-10-20 1987-10-19 Postupak za dobijanje peptida i novi peptidi YU46665B (sh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK503386A DK503386D0 (da) 1986-10-20 1986-10-20 Peptidpraeparater
DK356987A DK356987D0 (OSRAM) 1987-07-10 1987-07-10

Publications (2)

Publication Number Publication Date
YU191887A YU191887A (en) 1989-04-30
YU46665B true YU46665B (sh) 1994-01-20

Family

ID=26067111

Family Applications (1)

Application Number Title Priority Date Filing Date
YU191887A YU46665B (sh) 1986-10-20 1987-10-19 Postupak za dobijanje peptida i novi peptidi

Country Status (18)

Country Link
US (1) US5070186A (OSRAM)
EP (1) EP0265213B1 (OSRAM)
KR (1) KR880004819A (OSRAM)
CN (1) CN87107049A (OSRAM)
AU (1) AU616381B2 (OSRAM)
CA (1) CA1316819C (OSRAM)
DE (1) DE3778287D1 (OSRAM)
ES (1) ES2033871T3 (OSRAM)
FI (1) FI86254C (OSRAM)
GR (1) GR3004912T3 (OSRAM)
HU (1) HU201475B (OSRAM)
IE (1) IE60264B1 (OSRAM)
IL (1) IL84203A (OSRAM)
NO (1) NO170754C (OSRAM)
NZ (1) NZ222214A (OSRAM)
PH (1) PH23446A (OSRAM)
PT (1) PT85949B (OSRAM)
YU (1) YU46665B (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534488A (en) * 1993-08-13 1996-07-09 Eli Lilly And Company Insulin formulation
YU18596A (sh) * 1995-03-31 1998-07-10 Eli Lilly And Company Analogne formulacije monomernog insulina
EP1044016B1 (en) * 1998-01-09 2005-03-16 Novo Nordisk A/S Stabilised insulin compositions
US7678364B2 (en) 1999-08-25 2010-03-16 Alkermes, Inc. Particles for inhalation having sustained release properties
DE10114178A1 (de) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
ATE333260T1 (de) * 2001-08-27 2006-08-15 Novo Nordisk As Eine patrone und ein medizinisches anlieferungssystem das solch eine patrone unterbringt
KR20050090430A (ko) * 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
NZ571243A (en) * 2002-12-31 2010-04-30 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers comprising human growth hormone and protamine
JP2009521486A (ja) * 2005-12-23 2009-06-04 アルタス ファーマシューティカルズ インコーポレイテッド ポリカチオン錯化タンパク質結晶を含む組成物およびこれを使用した治療法
ES2542146T3 (es) 2006-07-31 2015-07-31 Novo Nordisk A/S Insulinas extendidas PEGiladas.
EP2404934A1 (en) 2006-09-22 2012-01-11 Novo Nordisk A/S Protease resistant insulin analogues
ES2563038T3 (es) 2007-04-30 2016-03-10 Novo Nordisk A/S Método para secar una composición proteica, una composición proteica seca y una composición farmacéutica que comprende la proteína seca
WO2008132229A2 (en) * 2007-04-30 2008-11-06 Novo Nordisk A/S Highly concentrated insulin solutions and compositions
US9260502B2 (en) 2008-03-14 2016-02-16 Novo Nordisk A/S Protease-stabilized insulin analogues
EP2910570B1 (en) 2008-03-18 2016-10-12 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
HRP20171894T1 (hr) 2008-10-17 2018-01-26 Sanofi-Aventis Deutschland Gmbh Kombinacija inzulina i agonista glp-1
MX2012005186A (es) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Composicion farmaceutica que comprende un agonista de glp-1, una insulina y metionina.
ES2965209T3 (es) 2009-11-13 2024-04-11 Sanofi Aventis Deutschland Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
CN101912600B (zh) * 2010-01-11 2014-01-29 杨国汉 改善胰岛素在溶液中稳定性的方法
US8637458B2 (en) * 2010-05-12 2014-01-28 Biodel Inc. Insulin with a stable basal release profile
AU2011202239C1 (en) 2010-05-19 2017-03-16 Sanofi Long-acting formulations of insulins
BR112013004756B1 (pt) 2010-08-30 2020-04-28 Sanofi Aventis Deutschland uso de ave0010 para a fabricação de um medicamento para o tratamento da diabetes melito tipo 2
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
RU2650616C2 (ru) 2011-08-29 2018-04-16 Санофи-Авентис Дойчланд Гмбх Фармацевтическая комбинация для применения при гликемическом контроле у пациентов с сахарным диабетом 2 типа
AR087744A1 (es) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
CN104364260B (zh) 2012-04-11 2017-02-22 诺和诺德股份有限公司 胰岛素制剂
US9399065B2 (en) 2012-04-16 2016-07-26 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and injection site pain of insulin
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
SG11201506888VA (en) 2013-04-03 2015-09-29 Sanofi Sa Treatment of diabetes mellitus by long-acting formulations of insulins
HRP20180468T1 (hr) 2013-10-07 2018-05-04 Novo Nordisk A/S Novi derivat analoga inzulina
PL3229828T3 (pl) 2014-12-12 2023-07-31 Sanofi-Aventis Deutschland Gmbh Formulacja o ustalonym stosunku insuliny glargine/liksysenatydu
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
EP3554534B1 (en) 2016-12-16 2021-06-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2076082A (en) * 1935-04-08 1937-04-06 Nordisk Insulinlab Therapeutic product and process
US2179384A (en) * 1937-04-05 1939-11-07 Univ Alberta Therapeutic composition and process of making it
US2190134A (en) * 1939-06-09 1940-02-13 Norton Co Grinding machine
US2538018A (en) * 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
US2474729A (en) * 1945-01-03 1949-06-28 Rhone Poulenc Sa Insulin preparations
US2801953A (en) * 1952-02-28 1957-08-06 Hoechst Ag Process of preparing crystallized insulin preparations
US3102077A (en) * 1953-08-19 1963-08-27 Christensen Henry Marinus Preparation of insulin containing 2.75 to 8 percent zinc content
DK98342C (da) * 1959-06-16 1964-03-31 Henry Marinus Dr Christensen Fremgangsmåde til fremstilling af et insulinpræparat til peroral applikation.
US3868358A (en) * 1971-04-30 1975-02-25 Lilly Co Eli Protamine-insulin product
GB1426061A (en) * 1972-12-28 1976-02-25 Ici Ltd Polypeptides
US3856771A (en) * 1973-07-16 1974-12-24 Lilly Co Eli Process for manufacturing alkali metal or ammonium insulin
US4196196A (en) * 1978-06-19 1980-04-01 Tiholiz Ivan C Divalen/monovalent bipolar cation therapy for enhancement of tissue perfusion and reperfusion in disease states
AU550068B2 (en) * 1981-03-10 1986-02-27 Novo Nordisk A/S Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
US4764592A (en) * 1987-04-23 1988-08-16 Eli Lilly And Company Crystalline human proinsulin and process for its production

Also Published As

Publication number Publication date
AU7990787A (en) 1988-04-21
FI86254C (fi) 1992-08-10
IL84203A (en) 1993-04-04
FI874596L (fi) 1988-04-21
PT85949B (pt) 1990-07-31
AU616381B2 (en) 1991-10-31
PT85949A (en) 1987-11-01
EP0265213B1 (en) 1992-04-15
US5070186A (en) 1991-12-03
NO170754B (no) 1992-08-24
KR880004819A (ko) 1988-06-27
NZ222214A (en) 1989-11-28
DE3778287D1 (de) 1992-05-21
CN87107049A (zh) 1988-07-06
IE872799L (en) 1988-04-20
NO874347L (no) 1988-04-21
NO874347D0 (no) 1987-10-19
HUT46232A (en) 1988-10-28
IE60264B1 (en) 1994-06-29
FI86254B (fi) 1992-04-30
EP0265213A2 (en) 1988-04-27
GR3004912T3 (OSRAM) 1993-04-28
ES2033871T3 (es) 1993-04-01
NO170754C (no) 1992-12-02
PH23446A (en) 1989-08-07
FI874596A0 (fi) 1987-10-19
EP0265213A3 (en) 1988-11-09
YU191887A (en) 1989-04-30
CA1316819C (en) 1993-04-27
HU201475B (en) 1990-11-28

Similar Documents

Publication Publication Date Title
YU46665B (sh) Postupak za dobijanje peptida i novi peptidi
YU46857B (sh) Postupak za dobijanje novih analoga insulina
Shapiro Limited proteolysis of some egg surface components is an early event following fertilization of the sea urchin, Strongylocentrotus purpuratus
SE452250C (sv) Sätt att framställa ett koncentrat av protrombinkomplex
IL79379A0 (en) Carboxylic acid derivatives,process for the preparation thereof and pharmaceutical compositions containing them
Ando et al. Effects of eel atrial natriuretic peptide on NaCl and water transport across the intestine of the seawater eel
Bell α, γ-Diaminobutyric acid in seeds of twelve species of Lathyrus and identification of a new natural amino-acid, L-homoarginine, in seeds of other species toxic to man and domestic animals
CA1338395C (en) Pharmaceutical containing tissue protein pp4, a process for the pasteurization of pp4, and the use of pp4
Thompson et al. Antidotal activity of British anti-lewisite against compounds of antimony, gold and mercury
Lamy et al. Octopus dofleini hemocyanin: structure of the seven-domain polypeptide chain
DE69322268T2 (de) Stabile zusammensetzung von polypeptiden
ATE69727T1 (de) Zusammensetzung zur behandlung von an haemophilia- a-inhibitor leidenden kranken.
Williams et al. Hydrolysis of peptide bonds of the oxidized B-chain of insulin by Endothia parasitica protease
Arthur et al. Experimental evidence for an enzymatic basis for itching in man
Reiser et al. A high-affinity inositol 1, 3, 4, 5-tetrakisphosphate receptor protein from brain is specifically labelled by a newly synthesized photoaffinity analogue, N-(4-azidosalicyl) aminoethanol (1)-1-phospho-D-myo-inositol 3, 4, 5-trisphosphate
Nomura et al. Structure and action of sperm activating peptides from the egg jelly of a sea urchin, Anthocidaris crassispina
Hubbard et al. Calmodulin-like activity in a mineralising tissue: the rat molar tooth germ
Barra et al. Hemoglobin components from trout (Salmo irideus): determination of the carboxyl and amino terminal sequences and their functional implications
ATE44750T1 (de) Verfahren zur herstellung eines antihaemophiliefaktor-konzentrats.
US2566123A (en) Stable vitamin b12 solution
Punnett et al. Partial purification and some chemical properties of the sperm chemoattractant from the forcipulate starfish Pycnopodia helianthoides (Brandt, 1835)
Samama et al. Crystallization and preliminary crystallographic data for bovine antithrombin III
Takahashi et al. The amino acid sequence of ribonuclease U1, a guanine-specific ribonuclease from the fungus Ustilago sphaerogena
Tsuru et al. Inactivation of Scytalidium lignicolum Acid Protease B with l, 2-Epoxy-3-(4′-azido-2/-nitrophenoxy) propane
Nose et al. Different roles of two consecutive leucine residues in a receptor-tethered ligand peptide (SFLLRNP) in thrombin receptor activation